Personal executive stock portfolios distort the federal regulation of metabolic medicine.
Highly irregular regulatory approvals, compounding bans, and single-patient expanded access pathways occur in direct lockstep with executive-level equity holdings in dominant pharmaceutical makers.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
Federal ethics disclosures link high-level policy support for GLP-1 coverage directly to underlying personal equity positions in a major manufacturer.
Single-patient expanded access for retatrutide lands in direct lockstep with the president's personal Eli Lilly stock purchases, repeating the pattern of aligned equity holdings distorting metabolic-drug regulation.
Ethics filings revealing presidential stock purchases during a series of major, highly lucrative regulatory actions benefiting Eli Lilly indicate direct systemic alignment.